This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mononen, N. Articles by Schleutker, J. Search for Related Content PubMed PubMed Citation Articles by Mononen, N. Articles by Schleutker, J.

Profiling Genetic Variation along the Androgen Biosynthesis and Metabolism Pathways Implicates Several Single Nucleotide Polymorphisms and Their Combinations as Prostate Cancer Risk Factors

¹ Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital; ² Research Unit, Tampere University Hospital; ³ Division of Urology, Tampere University Hospital and Medical School, University of Tampere; ⁴ Bioinformatics, Institute of Medical Technology, University of Tampere, Tampere, Finland; ⁵ National Human Genome Research Institute, NIH, Baltimore, Maryland; ⁶ Department of Molecular Medicine, National Public Health Institute, Helsinki, Finland; and ⁷ Medical Biotechnology, VTT-Technical Research Centre and University of Turku, Turku, Finland

Requests for reprints: Johanna Schleutker, Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere, Tampere FIN-33014, Finland. Phone: 358-3-3117-7601; Fax: 358-3-3117-4168; E-mail: Johanna.Schleutker{at}uta.fi.

Several candidate genes along androgen pathway have been suggested to affect prostate cancer risk but no single gene seems to be overwhelmingly important for a large fraction of the patients. In this study, we first screened for variants in candidate genes and then chose to explore the association between 18 variants and prostate cancer risk by genotyping DNA samples from unselected (n = 847) and familial (n = 121) prostate cancer patients and population controls (n = 923). We identified a novel single nucleotide polymorphism (SNP) in the CYP19A1 gene, T201M, with a mild significant association with prostate cancer [odds ratio (OR), 2.04; 95% confidence interval (95% CI), 1.03-4.03; P = 0.04]. Stratified analysis revealed that this risk was most apparent in patients with organ-confined (T₁-T₂) and low-grade (WHO grade 1) tumors (OR, 5.42; 95% CI, 2.33-12.6; P < 0.0001). In contrast, CYP17A1 –34T>C alteration was associated with moderate to poorly differentiated (WHO grade 2-3) organ-confined disease (OR, 1.42; 95% CI, 1.09-1.83; P = 0.007). We also tested a multigenic model of prostate cancer risk by calculating the joint effect of CYP19A1 T201M with five other common SNPs. Individuals carrying both the CYP19A1 and KLK3 –252A>G variant alleles had a significantly increased risk for prostate cancer (OR, 2.87; 95% CI, 1.10-7.49; P = 0.03). In conclusion, our results suggest that several SNPs along the androgen pathway, especially in CYP19A1 and CYP17A1, may influence prostate cancer development and progression. These genes may have different contributions to distinct clinical subsets as well as combinatorial effects in others illustrating that profiling and joint analysis of several genes along each pathway may be needed to understand genetic contributions to prostate cancer etiology. (Cancer Res 2006; 66(2): 743-7)

This article has been cited by other articles:

				R. C. Travis, F. Schumacher, J. N. Hirschhorn, P. Kraft, N. E. Allen, D. Albanes, G. Berglund, S. I. Berndt, H. Boeing, H. B. Bueno-de-Mesquita, et al. CYP19A1 Genetic Variation in Relation to Prostate Cancer Risk and Circulating Sex Hormone Concentrations in Men from the Breast and Prostate Cancer Cohort Consortium Cancer Epidemiol. Biomarkers Prev., October 1, 2009; 18(10): 2734 - 2744. [Abstract] [Full Text] [PDF]

				E. J. Payne, E. Ingley, I. M. Dick, S. G. Wilson, C. S. Bond, and R. L. Prince In Vitro Kinetic Properties of the Thr201Met Variant of Human Aromatase Gene CYP19A1: Functional Responses to Substrate and Product Inhibition and Enzyme Inhibitors J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2998 - 3002. [Abstract] [Full Text] [PDF]

				O. Cussenot, A. R. Azzouzi, N. Nicolaiew, G. Fromont, P. Mangin, L. Cormier, G. Fournier, A. Valeri, S. Larre, F. Thibault, et al. Combination of Polymorphisms From Genes Related to Estrogen Metabolism and Risk of Prostate Cancers: The Hidden Face of Estrogens J. Clin. Oncol., August 20, 2007; 25(24): 3596 - 3602. [Abstract] [Full Text] [PDF]

				S. Kury, B. Buecher, S. Robiou-du-Pont, C. Scoul, V. Sebille, H. Colman, C. Le Houerou, T. Le Neel, J. Bourdon, R. Faroux, et al. Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1460 - 1467. [Abstract] [Full Text] [PDF]

				J. M. Cunningham, S. J. Hebbring, S. K. McDonnell, M. S. Cicek, G. B. Christensen, L. Wang, S. J. Jacobsen, J. R. Cerhan, M. L. Blute, D. J. Schaid, et al. Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 969 - 978. [Abstract] [Full Text] [PDF]

				J. Lai, M.-A. Kedda, K. Hinze, R. L.G. Smith, J. Yaxley, A. B. Spurdle, C.P. Morris, J. Harris, and J. A. Clements PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility Carcinogenesis, May 1, 2007; 28(5): 1032 - 1039. [Abstract] [Full Text] [PDF]